PL1682131T3 - CCI-779 do leczenia chłoniaka do komórek płaszcza - Google Patents

CCI-779 do leczenia chłoniaka do komórek płaszcza

Info

Publication number
PL1682131T3
PL1682131T3 PL04796697T PL04796697T PL1682131T3 PL 1682131 T3 PL1682131 T3 PL 1682131T3 PL 04796697 T PL04796697 T PL 04796697T PL 04796697 T PL04796697 T PL 04796697T PL 1682131 T3 PL1682131 T3 PL 1682131T3
Authority
PL
Poland
Prior art keywords
cci
cell lymphoma
mantle cell
treating mantle
treating
Prior art date
Application number
PL04796697T
Other languages
English (en)
Inventor
Thomas E Witzig
Scott H Kaufmann
Original Assignee
Mayo Found Medical Education & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34590151&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1682131(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mayo Found Medical Education & Res filed Critical Mayo Found Medical Education & Res
Publication of PL1682131T3 publication Critical patent/PL1682131T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL04796697T 2003-11-04 2004-10-28 CCI-779 do leczenia chłoniaka do komórek płaszcza PL1682131T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51732903P 2003-11-04 2003-11-04
EP04796697A EP1682131B9 (en) 2003-11-04 2004-10-28 Cci-779 for treating mantle cell lymphoma
PCT/US2004/035900 WO2005046681A1 (en) 2003-11-04 2004-10-28 Cci-779 for treating mantle cell lymphoma

Publications (1)

Publication Number Publication Date
PL1682131T3 true PL1682131T3 (pl) 2008-02-29

Family

ID=34590151

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04796697T PL1682131T3 (pl) 2003-11-04 2004-10-28 CCI-779 do leczenia chłoniaka do komórek płaszcza

Country Status (31)

Country Link
US (2) US20050113403A1 (pl)
EP (1) EP1682131B9 (pl)
JP (1) JP4856548B2 (pl)
KR (1) KR101387988B1 (pl)
CN (1) CN1901906B (pl)
AR (1) AR046194A1 (pl)
AT (1) ATE373477T1 (pl)
AU (1) AU2004289213B2 (pl)
BR (1) BRPI0415714A (pl)
CA (1) CA2543665C (pl)
CO (1) CO5690605A2 (pl)
CR (1) CR8383A (pl)
DE (1) DE602004009098T2 (pl)
DK (1) DK1682131T3 (pl)
EC (1) ECSP066600A (pl)
ES (1) ES2291954T3 (pl)
GT (1) GT200400224A (pl)
HK (1) HK1088241A1 (pl)
IL (2) IL175128A0 (pl)
MY (1) MY136436A (pl)
NO (1) NO20062271L (pl)
PA (1) PA8616601A1 (pl)
PE (1) PE20051000A1 (pl)
PL (1) PL1682131T3 (pl)
PT (1) PT1682131E (pl)
RU (1) RU2358731C2 (pl)
SA (1) SA04250375B1 (pl)
TW (1) TW200517116A (pl)
UA (1) UA83697C2 (pl)
WO (1) WO2005046681A1 (pl)
ZA (1) ZA200603533B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
US20080207644A1 (en) * 2006-11-27 2008-08-28 Sonis Stephen T Therapeutic materials and methods
CN104017051B (zh) * 2014-06-23 2016-08-17 深圳市华中生物药械有限公司 一种Cyclin D 蛋白抑制剂多肽及其应用
CN104004060B (zh) * 2014-06-23 2016-04-13 重庆医科大学 Cyclin D蛋白抑制剂多肽及其应用
CN104031122B (zh) * 2014-06-23 2016-05-11 常州市肿瘤医院 有关Cyclin D蛋白抑制剂多肽及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
BR0113975A (pt) * 2000-09-19 2003-07-29 Wyeth Corp ésteres de rapamicina solúveis em água
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
US20030008923A1 (en) * 2001-06-01 2003-01-09 Wyeth Antineoplastic combinations
EA007530B1 (ru) 2001-06-01 2006-10-27 Уайт Противоопухолевые комбинации
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
EA008379B1 (ru) 2002-02-01 2007-04-27 Ариад Джин Терапьютикс, Инк. Фосфорсодержащие соединения и их применения
RU2344821C2 (ru) * 2002-07-30 2009-01-27 Уайт Парентеральные композиции, содержащие гидроксиэфиры рапамицина
MXPA05010582A (es) * 2003-04-22 2005-11-23 Wyeth Corp Combinaciones antineoplasicas.
TW200524864A (en) 2003-11-10 2005-08-01 Wyeth Corp Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab

Also Published As

Publication number Publication date
ES2291954T3 (es) 2008-03-01
MY136436A (en) 2008-10-31
WO2005046681A1 (en) 2005-05-26
CR8383A (es) 2006-10-04
DK1682131T3 (da) 2008-01-28
AU2004289213B2 (en) 2010-08-26
AU2004289213A1 (en) 2005-05-26
PA8616601A1 (es) 2006-06-02
US20110184010A1 (en) 2011-07-28
JP2007510721A (ja) 2007-04-26
ATE373477T1 (de) 2007-10-15
RU2358731C2 (ru) 2009-06-20
AR046194A1 (es) 2005-11-30
DE602004009098T2 (de) 2008-06-26
PE20051000A1 (es) 2006-02-03
EP1682131B1 (en) 2007-09-19
KR101387988B1 (ko) 2014-04-22
IL175128A0 (en) 2008-04-13
CO5690605A2 (es) 2006-10-31
US20050113403A1 (en) 2005-05-26
EP1682131A1 (en) 2006-07-26
RU2006119451A (ru) 2007-12-20
KR20060111559A (ko) 2006-10-27
CA2543665C (en) 2009-07-14
EP1682131B9 (en) 2009-03-25
BRPI0415714A (pt) 2006-12-19
CA2543665A1 (en) 2005-05-26
PT1682131E (pt) 2007-11-08
US8507518B2 (en) 2013-08-13
UA83697C2 (ru) 2008-08-11
CN1901906A (zh) 2007-01-24
DE602004009098D1 (de) 2007-10-31
ZA200603533B (en) 2007-07-25
HK1088241A1 (en) 2006-11-03
IL220080A0 (en) 2012-07-31
JP4856548B2 (ja) 2012-01-18
SA04250375B1 (ar) 2007-08-13
NO20062271L (no) 2006-07-21
TW200517116A (en) 2005-06-01
GT200400224A (es) 2005-06-06
ECSP066600A (es) 2006-10-25
CN1901906B (zh) 2011-11-16

Similar Documents

Publication Publication Date Title
EP1660026A4 (en) TREATMENT FOR CD5 + B CELL LYMPHOMA
PT1479187E (pt) Controlar níveis de acesso em telefones por certificados
SI1997512T1 (sl) Postopki za zdravljenje stanj, povezanih s TWEAK-om
EP1471902A4 (en) METHOD FOR TREATING HEARING LOSS
EP1989528A4 (en) CELL SUPPORT
IL220080A0 (en) Cci-779 for treating mantle cell lymphoma
GB2425617B (en) Device for preventing and treating myopia
EP1705740A4 (en) FUEL FOR FUEL CELL, FUEL CELL AND USE THEREOF
GB0206357D0 (en) Cells
HK1048599A1 (zh) 癌細胞植入抑制劑
GB0120311D0 (en) Treating cells
SI1682131T1 (sl) CCI-779 za zdravljenje limfoma plascnih celic
GB0326705D0 (en) Improved incontinence device
GB2403869B (en) Radiotelephone device
GB0407620D0 (en) Cell lines
GB2422600B (en) Sludge treatment
GB0323078D0 (en) Sewage treatment
GB0013817D0 (en) Method for treating cells
GB0223325D0 (en) Treating cancer
EP1660544A4 (en) ELIMINATION OF ARSENIC
TW592216U (en) Rapid sewage treatment device
IL158173A0 (en) Nanopatch-containing cells
IL153749A0 (en) Improvements for diapers
GB2400846B (en) Sewage treatment
AU2003901741A0 (en) Treatment for addiction